Pediatric Crohn's Disease Clinical Trial
Official title:
Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of TA-650 in Pediatric Patients With Moderate to Severe Crohn's Disease
The purpose of this study is to evaluate the efficacy of TA-650 using Pediatric Crohn's Disease Activity Index (PCDAI) in pediatric patients with moderate to severe Crohn's disease after TA-650 administration at a dose of 5 mg/kg at week 0, 2, and 6, then every 8 week after week 14 up to week 46, and at a dose of 10 mg/kg if the effect is attenuated. The safety and pharmacokinetics are also evaluated.
This is an open-label, uncontrolled, multicenter Phase 3 study conducted in Japan. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02578238 -
Post-Marketing Surveillance of Humira in Korean Pediatric Crohn's Disease (CD) Patients Under the "New-Drug Re-examination"
|
||
| Completed |
NCT02772965 -
Low Dose Oral Methotrexate in Pediatric Crohn's Disease Patients Initiating Anti-Tumor Necrosis Factor (Anti-TNF) Therapy
|
Phase 3 | |
| Completed |
NCT02869880 -
Trial of Enhanced Pre-Consent Discussion
|
N/A | |
| Withdrawn |
NCT01752790 -
Efficacy and Safety of Top-down Therapy in Pediatric Crohn's Disease
|
Phase 4 | |
| Terminated |
NCT02694042 -
Mission is Remission®: How Can a Disease Self-management Website Change Care?
|
N/A |